Bulletin
Investor Alert

Editas Medicine Inc.

NAS: EDIT

GO
/marketstate/country/us

After Hours

/zigman2/quotes/200426846/composite

$

38.44

Change

+0.62 +1.64%

Volume

Volume 11,523

Oct 22, 2021, 7:59 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/200426846/composite

Previous close

$ 38.47

$ 37.82

Change

-0.65 -1.69%

Day low

Day high

$36.86

$38.40

Open
Open: 38.40

52 week low

52 week high

$27.12

$99.95

Open

Market cap

$2.58B

Average volume

1.73M

P/E ratio

N/A

Rev. per Employee

$386,094

EPS

-2.55

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/edit

MarketWatch News on EDIT

  1. Prime Is the Newest Gene Editing, and It's Getting Better

    7:11 p.m. Oct. 20, 2021

    - Barron's Online

  2. The Man Behind Moderna on What’s Next in Biotech

    11:49 p.m. Oct. 15, 2021

    - Barron's Online

  3. This Fund Is Winning Big by Betting on Stocks That Help Humanity

    7:37 a.m. Sept. 27, 2021

    - Barron's Online

  4. Editas Medicine started at hold with $65 stock price target at Stifel Nicolaus

    7:59 a.m. Sept. 24, 2021

    - Tomi Kilgore

  5. Editas Medicine upgraded to outperform from perform at Oppenheimer

    7:28 a.m. Sept. 10, 2021

    - Tomi Kilgore

  6. Editas Medicine upgraded to buy from hold at Truist

    8:11 a.m. Aug. 9, 2021

    - Tomi Kilgore

  7. Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough

    9:21 a.m. June 30, 2021

    - Barron's Online

  8. First In-Vivo Gene Editing Data Look Good for Intellia

    8:40 a.m. June 28, 2021

    - Barron's Online

  9. Why ARK Innovation Is a Different Fund Today Than It Was a Year Ago

    7:24 a.m. March 29, 2021

    - Barron's Online

  10. Biotech stocks are a buy — especially these 18 picks

    2:02 p.m. March 13, 2021

    - Michael Brush

  11. Editas Medicine downgraded to hold from buy at Truist

    9:05 a.m. Feb. 26, 2021

    - Tomi Kilgore

  12. Editas Medicine downgraded to market perform from outperform at Raymond James

    8:50 a.m. Jan. 8, 2021

    - Tonya Garcia

  13. The 12 Most Overpriced Stocks in America

    8:48 a.m. Dec. 28, 2020

    - Barron's Online

  14. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/edit

Other News on EDIT

  1. 2 Tricks and a Treat for Gene Therapy Investors

    6:45 a.m. Oct. 18, 2021

    - Motley Fool

  2. What's Hot in the Stock Market?

    3:15 p.m. Oct. 11, 2021

    - Motley Fool

  3. Editas Medicine (EDIT) Investor Presentation - Slideshow

    1:11 p.m. Oct. 8, 2021

    - Seeking Alpha

  4. Intellia Therapeutics slides after insider selling

    10:56 a.m. Oct. 8, 2021

    - Seeking Alpha

  5. 3 Spooky Healthcare Stocks I Would Avoid in October

    7:18 a.m. Oct. 7, 2021

    - Motley Fool

  6. Investment Case On ProQR Therapeutics Gets More Enticing

    3:06 p.m. Oct. 1, 2021

    - Seeking Alpha

  7. Editas (EDIT) Down on Initial Data From Eye Disease Study

    10:37 a.m. Sept. 30, 2021

    - Zacks.com

  8. Loading more headlines...
/news/pressrelease/company/us/edit

Press Releases on EDIT

  1. Aadi Bioscience Appoints Emma Reeve to its Board of Directors

    8:00 a.m. Sept. 13, 2021

    - GlobeNewswire

  2. Editas Medicine Names Emma Reeve to Board of Directors

    9:00 a.m. Sept. 8, 2021

    - GlobeNewswire

  3. Editas Medicine to Participate in Upcoming Investor Conferences

    8:00 a.m. Sept. 2, 2021

    - GlobeNewswire

  4. Loading more headlines...

Rates »

Link to MarketWatch's Slice.